Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
Jean‐Pascal Machiels(Cliniques Universitaires Saint-Luc), Ana Paula Victorina, Christian Simon(University of Lausanne), Thorsten Fuereder(Medical University of Vienna), Pedro Rafael Martins De Marchi, Makoto Tahara(National Cancer Center Hospital East), Margaret McGrath(The University of Queensland), S. Deheneffe, Barbara Burtness(Yale University), Y. Pointreau(Centre Hospitalier Universitaire de Nantes), Gustavo Vasconcelos Alves(Marqués de Valdecilla University Hospital), Jean‐Pierre Delord, Martin Burian(Ordensklinikum Linz Barmherzige Schwestern), Marcin Hetnał(Andrzej Frycz Modrzewski Krakow University), Ramona F. Swaby(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrea Juliana Gomes, John Waldron(Princess Margaret Cancer Centre), Miren Taberna(Institut Català d'Oncologia), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Tatiane Cardoso Motta, Richard Greil(Paracelsus Medical University), Iane Pinto Figueiredo Lima, Sylvie Rottey(Ghent University Hospital), Yungan Tao(Université Paris-Saclay), Lisa Licitra(University of Milan), Brett Hughes(Royal Brisbane and Women's Hospital), Sercan Aksoy(Hacettepe University Hospital), Behzad Bidadi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Burak Gümüşçü(Merck & Co., Inc., Rahway, NJ, USA (United States)), Danny Rischin(Peter MacCallum Cancer Centre), Josiane Mourão Dias(Harbin Medical University), Simon Laban(University Hospital Ulm), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Bo Gao(Regeneron (United States)), Stéphanie Henry(CHU Dinant Godinne UCL Namur), Mônica Luciana Agostinho Padoan, Milena Perez Mak, Yayan Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paul Clement(KU Leuven), Lillian L. Siu(University Health Network), Vincent Grégoire(Centre Léon Bérard), Dietmar Thurnher(Vienna General Hospital)
Cited by 223
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856